Answers are grounded in this paper and cite their sources.
Background and Objective: Uterine sarcomas are very rare, extremely aggressive, and often associated with poor outcomes. They include different histological variants, Leiomyosarcoma being the most common one and the most represented uterine sarcoma in clinical studies. We have reviewed the medical treatment of uterine sarcomas focusing on the available options for adjuvant therapy and for advanced, metastatic or recurrent disease, including the new targeted therapies that are currently being developed. Methods: A MEDLINE (PubMed) search of the literature was performed, focusing on papers published in the last two decades.
No takes yet. Share an insight, caveat, or question.
Ferrero et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: